Evidence map›Paper›PMID 26563285›Full record

ReviewSeminars in immunopathology2016

Cutaneous dermatomyositis in the era of biologicals.

Natalie A Wright, Ruth Ann Vleugels, Jeffrey P Callen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Seminars in immunopathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Natalie A WrightBrigham and Women's Hospital, Department of Dermatology, 221 Longwood Ave, Boston, MA, 02115, USA.
Ruth Ann VleugelsBrigham and Women's Hospital, Department of Dermatology, 221 Longwood Ave, Boston, MA, 02115, USA.
Jeffrey P CallenDepartment of Medicine, Division of Dermatology, University of Louisville, 3810 Springhurst Blvd, Louisville, KY, 40241, USA. jeffreycallen01@gmail.com.
Brigham and Women's Hospital · USUniversity of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatomyositis (DM) is a systemic inflammatory condition characterized by cutaneous and muscle findings, in addition to potential involvement of other organ systems. A distinct subtype of DM exists that is categorized by cutaneous findings with absent or minimal muscle involvement, referred to as clinically amyopathic dermatomyositis or dermatomyositis sine myositis. A variety of topical, immunosuppressive, and immunomodulatory therapies have been utilized to treat cutaneous DM. The advent of biological agents including tumor necrosis factor-α antagonists, intravenous immunoglobulin, rituximab, and others has allowed for the use of these agents with varying degrees of success for the treatment of cutaneous DM.

Indexed as

Biological ProductsDermatomyositisHumansImmunoglobulins, IntravenousImmunologic FactorsRituximabTumor Necrosis Factor-alphaBiological ProductsImmunoglobulins, IntravenousImmunologic FactorsRituximabTumor Necrosis Factor-alphaAmyopathic dermatomyositisBiologicalsCutaneous dermatomyositisIntravenous immunoglobulinRituximabTNF-α antagonists

Identifiers

PMID26563285
OpenAlexW2180566442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.